Loading...
01/11 04:08
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals a mixed financial performance with a significant revenue decline and a shift from operating income to loss. While there is optimism in strategic partnerships and market expansion, the Q&A section highlights uncertainties, especially regarding FDA approval impacts and international sales efforts. The lack of specific guidance and vague responses to key questions further dampen sentiment. Despite some positive long-term prospects, immediate financial challenges and unclear management responses suggest a negative short-term market reaction.
Revenue for Q3 2025 $2 million, a 24% decrease from $2.5 million in Q3 2024. The decline was primarily due to a timing reduction in iHP services sales from a key customer who reorganized its operations. This impact is expected to be temporary.
Sequential Revenue Growth 95% increase from Q2 2025 to Q3 2025, driven by expanding recurring revenue streams and deeper customer engagement.
Recurring BIT Solution Sales Increased 21% year-to-date compared to 2024, attributed to a focus on existing customer base, implementation, usage, and tailored protocol development.
Sales Order Backlog $0.9 million at the end of Q3 2025, growing to $1.3 million by October 31, 2025. Approximately $3 million in pending SteraMist Integration Contracts expected to close before year-end.
Gross Profit Margins 61% for Q3 2025, consistent with the same period in 2024, reflecting resilience in product mix and disciplined cost management.
Operating Loss for Q3 2025 Approximately $320,000, compared to an operating income of $149,000 in Q3 2024.
Net Loss for Q3 2025 Approximately $450,000 or $0.02 per share, compared to a net income of $58,000 in Q3 2024.
Cash and Cash Equivalents Approximately $190,000 as of September 30, 2025.
Working Capital $2.5 million as of September 30, 2025.
Shareholder Equity $2.2 million as of September 30, 2025.
Recurring revenue growth: Recurring BIT Solution sales have risen 21% year-to-date, contributing significantly to the company's revenue growth.
Capital equipment sales: Increased capital purchases of mobile equipment by service provider partners, including industry leaders and smaller players.
New product adoption: SteraMist iHP technology continues to gain industry recognition and adoption, including being named the disinfection and decontamination products company of the year 2025.
Regulatory developments: FDA's broadened approval of hydrogen peroxide opens new markets in agriculture, food processing, and environmental biosafety.
International expansion: Active pipeline surpasses $15 million, including domestic and international customers, with $3 million in pending SteraMist Integration Contracts expected to close before year-end.
New partnerships: Collaboration with Nestle to establish SteraMist technology as a global standard across their nutritional facilities worldwide.
Operational efficiency: Gross profit margins remain strong at 61%, reflecting disciplined cost management and a resilient product mix.
Customer engagement: Focus on tailored protocol development and training programs to enhance customer implementation and usage.
Sales strategy: Sales backlog grew from $0.9 million to $1.3 million by October 31, with a strong pipeline of $15 million.
Strategic partnerships: Entered into an equity purchase agreement with Hudson Global Ventures for up to $20 million in common stock over 24 months to fund growth initiatives.
Market positioning: Positioning SteraMist iHP technology as a benchmark for sterile environments in pharmaceutical and other industries.
Future focus: Sharpening focus on biosecurity advancements, automation integrations, and sustainable agricultural opportunities heading into 2026.
Revenue Decline: The company experienced a 24% decrease in revenue in Q3 2025 compared to Q3 2024, primarily due to a temporary reduction in iHP service sales from a key customer who reorganized its operations.
Operating Loss: The company reported an operating loss of approximately $320,000 in Q3 2025, compared to an operating income of $149,000 in the same period last year.
Net Loss: The net loss for Q3 2025 was approximately $450,000, compared to a net income of $58,000 in Q3 2024.
Cash Position: As of September 30, 2025, the company had cash and cash equivalents of approximately $190,000, which may limit its ability to fund operations and growth initiatives without additional financing.
Extended CES Timelines: The custom-engineered system (CES) has extended timelines from initial interest to full commissioning, which can be expensive and delay revenue realization.
Regulatory and Market Risks: While regulatory changes like FDA approval of hydrogen peroxide open new markets, they also require significant investment in R&D and market expansion, which could strain resources.
Supply Chain Vulnerabilities: The company highlighted the need to address supply chain vulnerabilities as part of its biosecurity advancements, indicating potential risks in maintaining consistent operations.
Dependence on Key Customers: The temporary reduction in service sales from a key customer underscores the risk of over-reliance on a limited number of major clients.
Competitive Pressures: The company operates in highly competitive markets, including life sciences, food safety, and health care, which may impact its ability to maintain or grow market share.
Capital Requirements: The company entered into an equity purchase agreement to raise up to $20 million, indicating a need for additional capital to fund operations, R&D, and market expansion.
Revenue Growth: The company anticipates continued growth in recurring BIT Solution sales, capital equipment sales, and custom integrations. The active pipeline is valued at over $15 million, with $3 million in pending SteraMist Integration Contracts expected to close before year-end 2025.
Market Expansion: TOMI is focusing on biosecurity advancements, scaling automation integrations, and exploring opportunities in sustainable agriculture and public infrastructure. The company is also targeting the food safety market, leveraging FDA regulatory changes to expand applications of SteraMist.
Strategic Partnerships: The company is strengthening relationships with major pharmaceutical companies like Merck, Eli Lilly, and AstraZeneca, and expanding its presence in the academic and healthcare sectors. It is also pursuing collaborations in the cannabis market and food safety industry.
Product Development: TOMI is prioritizing the development of hybrid and SIS products for faster integration and revenue realization. The company is also enhancing training programs and certifications to drive product adoption and customer engagement.
Financial Strategy: The company has entered into an equity purchase agreement with Hudson Global Ventures, allowing access to up to $20 million in capital over 24 months to fund growth initiatives, R&D, and market expansion.
The selected topic was not discussed during the call.
The earnings call reveals a mixed financial performance with a significant revenue decline and a shift from operating income to loss. While there is optimism in strategic partnerships and market expansion, the Q&A section highlights uncertainties, especially regarding FDA approval impacts and international sales efforts. The lack of specific guidance and vague responses to key questions further dampen sentiment. Despite some positive long-term prospects, immediate financial challenges and unclear management responses suggest a negative short-term market reaction.
Despite positive developments like high solution sales margins and potential opportunities in pharma manufacturing, the earnings call reveals significant challenges. A 66% revenue decline, increased operating losses, and regulatory hurdles dampen optimism. The Q&A highlights deferred CapEx projects and vague management responses, adding uncertainty. While there are growth prospects, the lack of concrete timelines and financial guidance tempers expectations. Overall, the mixed signals suggest a neutral stock price movement.
The earnings call reflects strong financial performance, with a 42% increase in sales and improved margins and losses. However, the lack of a shareholder return plan and vague guidance for 2025 temper the positive sentiment. The Q&A reveals concerns about regulatory and supply chain issues, and management's unclear responses on tariffs and financial goals add uncertainty. Despite the positive revenue growth, the absence of clear guidance and shareholder return plans, along with operational risks, suggest a neutral stock price movement in the short term.
The earnings call reveals a 42% revenue increase and reduced operating losses, indicating improved financial performance. Despite management's lack of clear guidance for 2025, strong growth in product and service revenues, along with a significant sales backlog, suggests positive momentum. The Q&A section highlights increased interest in food safety applications and potential regulatory advancements, which could drive demand. While regulatory challenges and unclear guidance are concerns, the overall sentiment is positive due to strong financial results and growth prospects.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
